Related Experiment Video

Updated: Sep 4, 2025

Retinal and Choroidal Thickness Changes in Populations with Helicobacter pylori Infection by Swept-Source Optical Coherence Tomography
03:47

Retinal and Choroidal Thickness Changes in Populations with Helicobacter pylori Infection by Swept-Source Optical Coherence Tomography

Published on: November 1, 2024

272

The effect of Helicobacter pylori eradication on C-reactive protein: results from a meta-analysis

Jun Watanabe1, Kazuhiko Kotani1

  • 1Division of Community and Family Medicine, Jichi Medical University, Shimotsuke city, Japan.

Archives of Medical Science : AMS
|July 14, 2022
PubMed
Abstract

Insights

Eradicating Helicobacter pylori infection may reduce C-reactive protein (CRP) levels, a marker of inflammation. However, current evidence is limited, and further research is needed to confirm this effect.

Area of Science:

  • Gastroenterology
  • Infectious Diseases
  • Inflammation Markers

Background:

  • Helicobacter pylori infection is linked to chronic gastroduodenal issues and systemic diseases.
  • Elevated C-reactive protein (CRP) indicates low-grade chronic inflammation in H. pylori infected individuals.
  • The impact of H. pylori eradication on CRP levels requires further investigation.

Purpose of the Study:

  • To evaluate the effect of H. pylori eradication on circulating C-reactive protein (CRP) levels.
  • To conduct a meta-analysis of studies examining CRP changes post-eradication.

Main Methods:

  • A comprehensive literature search of the PubMed database was conducted up to June 2020.
  • Eligible studies reporting CRP levels before and after H. pylori eradication were included.
  • A random-effects meta-analysis using inverse variance and standardized mean difference was performed.

Main Results:

  • Ten studies comprising 642 subjects were analyzed.
  • A statistically significant reduction in CRP levels was observed following H. pylori eradication (SMD: -0.64).
  • This reduction was not consistently found in the subanalysis of randomized controlled trials.

Conclusions:

  • Limited evidence suggests H. pylori eradication may lower CRP levels.
  • Further high-quality research, particularly randomized controlled trials, is necessary to substantiate these findings.
Keywords:
C-reactive proteinHelicobacter pylorianti-bacterial therapyinflammation

More Related Videos

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

485
One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode10:44

One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode

Published on: June 18, 2016

9.8K

Related Concept Videos

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
530
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
192
Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
275
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
515
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
565
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
141